Drug Profile
Research programme: cancer vaccines - OncoSenescence
Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator OncoSenescence
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
- 10 Aug 2016 Preclinical development is ongoing in USA
- 12 Aug 2013 Preclinical trials in Cancer in USA (Parenteral)